Frankfurt
22.06.26 | 08:12
39,000 Euro
+1,56 % +0,600
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:06 | Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026 | 1 | GlobeNewswire (USA) | ||
| 15.06. | Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2026 | 4 | GlobeNewswire (USA) | ||
| 08.06. | Ipsen Pharma: Ipsen - May 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital | 2 | GlobeNewswire (USA) | ||
| 08.06. | Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2026 | 1 | GlobeNewswire (USA) | ||
| 04.06. | Dividendenbekanntmachungen (04.06.2026) | 13.139 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-LIVING SMART CITY SERVICES CO LTD CNE100002RY5 0,0688 HKD 0,0075 EUR ADESSO SE DE000A0Z23Q5 - 0,78 EUR AGEAS SA/NV ADR US00844W2089 2... ► Artikel lesen | |
| 01.06. | Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2026 | 2 | GlobeNewswire (USA) | ||
| 29.05. | Ipsen Pharma: Ipsen announces the launch of an Employee Shareholding Plan | 543 | GlobeNewswire (Europe) | Ipsen announces the launch of an employee shareholding plan PARIS, FRANCE, 29 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the launch of an employee shareholding plan. This fifth transaction... ► Artikel lesen | |
| IPSEN SA ADR Aktie jetzt für 0€ handeln | |||||
| 28.05. | Ipsen Pharma: New late-breaking data reinforces IQIRVO's impact on ALP, fatigue and pruritus in PBC | 700 | GlobeNewswire (Europe) | IQIRVO data expands scientific evidence in fatigue, showing clinically meaningful improvements in patients with moderate-to-severe fatigue at baselineIn the first real-world analysis in patients with... ► Artikel lesen | |
| 27.05. | Ipsen Pharma: IPSEN - Buy-back programme - Art 5 of MAR - Week 21 - 2026 | 1 | GlobeNewswire (USA) | ||
| 19.05. | Ipsen Pharma: Ipsen announces late-breaking data from first head-to-head study comparing Dysport and Botox in adults with upper limb spasticity | 904 | GlobeNewswire (Europe) | Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpointsThe DIRECTION trial results show the safety profile for Dysport (abobotulinumtoxinA) was... ► Artikel lesen | |
| 18.05. | Ipsen Pharma: Ipsen - April 2026- Monthly information relative to the total number of voting rights and shares composing the share capital | 1 | GlobeNewswire (USA) | ||
| 18.05. | Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3 | 3 | FierceBiotech | ||
| 18.05. | Ipsen Pharma: Ipsen initiates a new share buy-back program | 4 | GlobeNewswire (USA) | ||
| 16.05. | Ipsen: Corabotase Data Demonstrate Rapid, Durable Efficacy In Glabellar Lines | 669 | AFX News | PARIS (dpa-AFX) - Ipsen SA (IPN.PA, IPSEY) presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen's... ► Artikel lesen | |
| 16.05. | Ipsen Pharma: Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction | 1.002 | GlobeNewswire (Europe) | Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically... ► Artikel lesen | |
| 14.05. | Ipsen Pharma: Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI, at the SCALE Symposium | 404 | GlobeNewswire (Europe) | Corabotase is the first investigational molecule in a newly designated class of recombinant neuroinhibitors, RNITM, as recognized by the WHO and USAN Phase II data in glabellar (frown) lines to be... ► Artikel lesen | |
| 13.05. | Ipsen Pharma: Ipsen S.A. - Evolution of the composition of the Board of Directors | 237 | GlobeNewswire (Europe) | Ipsen S.A. - Evolution of the composition of the Board of Directors PARIS, FRANCE, 13 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Mrs. Karen Witts has resigned from her position... ► Artikel lesen | |
| 13.05. | Ipsen Pharma: Annual General Meeting of Ipsen S.A. held on 13 May 2026 | 268 | GlobeNewswire (Europe) | Annual General Meeting of Ipsen S.A. held on 13 May 2026 All the resolutions submitted to the shareholders' vote have been adopted PARIS, FRANCE, 13 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announces... ► Artikel lesen | |
| 06.05. | Ipsen scuttles liver disease candidates from $952M Albireo acquisition | 2 | FierceBiotech | ||
| 23.04. | Ipsen Q1 2026 slides: rare disease portfolio drives 22.6% sales growth | 5 | Investing.com |
1 2 3 4 5 Weiter >>
96 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 108,48 | +0,63 % | Dividendenbekanntmachungen (15.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2966 EUR AEGON LTD ADR US0076CA1045 0,2468 USD 0,2134 EUR AGROB IMMOBILIEN... ► Artikel lesen | |
| INNOCAN PHARMA | 1,680 | -12,04 % | InnoCan Pharma unter massivem Druck: Was die wenigsten Anleger auf dem Schirm haben - Was erfahrene Trader jetzt tun | ||
| IONIS PHARMACEUTICALS | 64,20 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 196,70 | +0,67 % | AbCellera Biologics Inc.: Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies | The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop... ► Artikel lesen | |
| JAGUAR HEALTH | 2,400 | +6,67 % | Jaguar Health, Inc.: Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program | Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development program for rare intestinal... ► Artikel lesen | |
| KALA BIO | 3,340 | -7,48 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,040 | -1,30 % | IRONWOOD PHARMACEUTICALS INC - 8-K, Current Report | ||
| GALECTIN THERAPEUTICS | 2,500 | +1,63 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,350 | -1,26 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update | Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined... ► Artikel lesen | |
| MINDWALK | 1,350 | +2,27 % | Highflyer der Zukunft - "Must Have" für ihr Biotech-Depot?! | ||
| KAZIA THERAPEUTICS | 14,000 | +1,01 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,250 | -1,57 % | InMed Pharmaceuticals: InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements | Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,450 | -3,16 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model | Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator... ► Artikel lesen | |
| LIPOCINE | 2,320 | -0,43 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,359 | -1,21 % | Heron Therapeutics: Aktionäre stimmen auf jährlicher Hauptversammlung allen Vorschlägen zu |
IPSEN SA ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,600 (+1,56 %) liegt der Kurs bei 39,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IPSEN SA ADR finden Sie auf Wallstreet Online.